ArticleScientific reports2018
Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Lower respiratory tract microbiota characteristics in patients withFrontiers in cellular and infection microbiology · 2026Article
- From computational screening toFrontiers in microbiology · 2026Article
- Rational Design, Computational Analysis and Antibacterial Activities of Synthesized Peptide-Based Molecules Targeting Quorum Sensing-Dependent Biofilm Formation inPharmaceuticals (Basel, Switzerland) · 2025Article
- The Marine Antimicrobial Peptide AOD with Intact Disulfide Bonds Has Remarkable Antibacterial and Anti-Biofilm Activity.Marine drugs · 2024Article
- Effect of L-arginine on cystic fibrosisAntimicrobial agents and chemotherapy · 2024Article
- Lack of correlation betweenHeliyon · 2024Article
- Developing antibacterial peptides as a promising therapy for combating antibiotic-resistantVeterinary world · 2024Article
- Interaction of designed cationic antimicrobial peptides with the outer membrane of gram-negative bacteria.Scientific reports · 2024Article
- In Silico and In vitro Evaluations of the Antibacterial Activities of HIV-1 Nef Peptides againstInternational journal of molecular and cellular medicine · 2024Article
- Recent Progress in the Characterization, Synthesis, Delivery Procedures, Treatment Strategies, and Precision of Antimicrobial Peptides.International journal of molecular sciences · 2023Review
- In vitro and in vivo antibiofilm activity of the synthetic antimicrobial peptide WLBU2 against multiple drug resistant Pseudomonas aeruginosa strains.BMC microbiology · 2023Article
- Study on Optimizing Novel Antimicrobial Peptides with Bifunctional Activity to Prevent and Treat Peri-Implant Disease.Antibiotics (Basel, Switzerland) · 2022Article
- Tobramycin-loaded complexes to prevent and disrupt Pseudomonas aeruginosa biofilms.Drug delivery and translational research · 2022Article
- Antimicrobial Peptides against Multidrug-ResistantJournal of medicinal chemistry · 2022Article
- Tryptone in Growth Media EnhancesMicroorganisms · 2022Article
- Treatment ofFrontiers in microbiology · 2022Review
- Co-expression Mechanism Analysis of Different Tachyplesin I-Resistant Strains inFrontiers in microbiology · 2022Article
- Review
- The role of Psl in the failure to eradicate Pseudomonas aeruginosa biofilms in children with cystic fibrosis.NPJ biofilms and microbiomes · 2021Article
- Biofilms in Diabetic Foot Ulcers: Impact, Risk Factors and Control Strategies.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increasing recognition of biofilms in human disease, the development of novel antimicrobial therapies is of critical importance. For example, in patients with cystic fibrosis (CF), the acquisition of host-adapted, chronic Pseudomonas aeruginosa infection is associated with a decline in lung function and increased mortality. Our objective was to test the in vitro efficacy of a membrane-active antimicrobial peptide we designed, termed 6K-F17 (sequence: KKKKKK-AAFAAWAAFAA-NH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.